Why TPST rose 48.3% on Sep 16 2026: cell therapy option
TPST+48.3%on Wed Sep 16 2026
Tempest Therapeutics, Inc. Common Stock was up 48.3% on the day at $1.12, ranked #5 on — its usual five-minute volume, when TapeRank recorded this spike at 04:01 ET during the pre-market session.
THE DAY ON THE LIST · 1 EVENT
- 04:01 ETMOVER · PRE-MARKET
$1.12 · ▲ 48.3% ON THE DAY · — 5M RVOL · RANK #5
JUSTIFIEDCONFIDENCE4/5TPST rose 56.2% after announcing an exclusive option to license Senlang’s CD7-targeted platform and in vivo CAR-T candidates, including a Phase 1 multiple-myeloma program. The catalyst expands its pipeline but remains an option agreement with no disclosed economics, while a recent $2.5 million placement adds substantial potential share issuance.
WHYA 56.2% move is broadly supported by a new oncology pipeline deal, but the unquantified option structure and early-stage assets make the reaction somewhat aggressive.ANALYZED 04:01 ET · <1 MIN AGO · OPENAI/GPT-5.6-LUNATHE ROW AND SESSION LEVELS AT 04:01 ET
LAST1.12DAY▲ 48.3%5 MIN▼ 2.61%5M RVOL—5M $VOL$504KFLOAT*16.5MRANK#5SESSIONPRE-MARKETVWAP1.17HOD1.21LOD1.09OR HIGH—OR LOW—PREV CLOSE0.7554PM HIGH1.21PM LOW1.09GAP▲ 56.17% (indicated)* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
— MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO
THE SESSION
- 09:30 ETOpened at $1.07, +41.6% on the previous close of $0.7554
- 11:47 ETRegular-session low, $0.9674
- 14:19 ETRegular-session high, $1.48
- 15:59 ETLast trade of the regular session, $1.21, +60.0% on the previous close of $0.7554
- Volume: 78.2M shares in regular hours, 22.3M before the open
TPST opened at $1.07, already well above the previous close, then slipped to a session low of $0.9674 at 11:47 ET before climbing to $1.48 at 14:19 ET and ending at $1.21, still 60.0% above the prior close. There were no halts. TapeRank read the move as justified by Tempest’s exclusive option to license Senlang’s CD7-targeted platform and in vivo CAR-T candidates, including a Phase 1 multiple-myeloma program, while noting that the agreement had no disclosed economics and that a recent $2.5 million placement could add share issuance.
WRITTEN THU OCT 15 2026 17:50 ET BY OPENAI/GPT-5.6-LUNA FROM THE FACTS ON THIS PAGE
FILINGS AND NEWS · 24H BEFORE THE MOVE
- 00:07 ETTempest Therapeutics (TPST) Stock Climbs Over 66% After Hours: Here's WhyBenzinga
- TUE 16:06 ETTempest Therapeutics Enters Into Exclusive Option Agreement To License Senlang's CD7-Targeted Lentiviral Vector Platform And Portfolio Of In Vivo CAR-T Product CandidatesBenzinga
- TUE 16:06 ET8-K — Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities; Financial Statements and ExhibitsSEC 8-K
On the tape right now
WHERE THE LIST STOODWED NOV 4 2026 · 13:49 ETRECORDED LIVE · 742 QUALIFY
Open the full list